Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients
Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that removes platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to individual differences in the outcome of patients after chemotherapy. This study aims...
Gespeichert in:
| Veröffentlicht in: | PloS one 2012-03, Vol.7 (3), p.e33200-e33200 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e33200 |
|---|---|
| container_issue | 3 |
| container_start_page | e33200 |
| container_title | PloS one |
| container_volume | 7 |
| creator | Wu, Wenting Li, Huan Wang, Huibo Zhao, Xueying Gao, Zhiqiang Qiao, Rong Zhang, Wei Qian, Ji Wang, Jiucun Chen, Hongyan Wei, Qingyi Han, Baohui Lu, Daru |
| description | Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that removes platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to individual differences in the outcome of patients after chemotherapy. This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment were enrolled in this study. Four potentially functional XPD polymorphisms (Arg(156)Arg, Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or PCR-based sequencing.
Variant genotypes of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln were significantly associated with poorer NSCLC survival (P = 0.006, 0.006, 0.014, respectively, by log-rank test). The most common haplotype GCA (in order of Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) also exhibited significant risk effect on NSCLC survival (log-rank P = 0.001). This effect was more predominant for patients with stage IIIB disease (P = 2.21×10(-4), log-rank test). Increased risks for variant haplotypes of XPD were also observed among patients with performance status of 0-1 and patients with adenocarcinoma. However, no significant associations were found between these polymorphisms, chemotherapy response and PFS.
Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy. |
| doi_str_mv | 10.1371/journal.pone.0033200 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1324393892</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477004260</galeid><doaj_id>oai_doaj_org_article_d0d2b632b8944920b00b8a7df19d5d1e</doaj_id><sourcerecordid>A477004260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c691t-c51b357d0758db9a61ac98b8669a8cd5b92582a58e4698ee603397c4fe0f2bb43</originalsourceid><addsrcrecordid>eNqNk12L1DAUhoso7jr6D0QDguJFx3z0KzfCMq46sLDiF96FND2dZkmTmrTi3PrLzex0lxnZCym0IX3Oe855k5MkTwleElaSN1du8laa5eAsLDFmjGJ8LzklnNG0oJjdP1ifJI9CuMI4Z1VRPExOKM1Kzgp-mvw5b1tQI3ItGpzZ9s4PnQ59QNqiH5_eIWeRMtpqJQ1y06hcD-EaNnLUdurTWgZokOqgd2MHXg5b1DqPVp22EABZZ9PQS2OQgvgyk90gJa0Cj4aoAHYMj5MHrTQBnszfRfLt_fnX1cf04vLDenV2kaqCkzFVOalZXja4zKum5rIgUvGqjg1xWakmrznNKyrzCrKCVwBFtISXKmsBt7SuM7ZInu91B-OCmO0LgjCaMc4qTiOx3hONk1di8LqXfiuc1OJ6w_mNkH7UyoBocEPrgtG64lnGKa4xritZNi3hTd4QiFpv52xT3UOjYqdemiPR4z9Wd2LjfgnGSJ7nu2JezQLe_ZwgjKLXYWeitOCmIDinFS32Zb_4h7y7uZnayFi_tq2LadVOU5xlZYlxRqNli2R5BxWfBnqt4lVrddw_Cnh9FBCZEX6PGzmFINZfPv8_e_n9mH15wHYgzdgFZ6ZROxuOwWwPKu9C8NDeekyw2E3KjRtiNylinpQY9uzwfG6DbkaD_QVFFQ8b</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1324393892</pqid></control><display><type>article</type><title>Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients</title><source>Public Library of Science (PLoS) Journals Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Wu, Wenting ; Li, Huan ; Wang, Huibo ; Zhao, Xueying ; Gao, Zhiqiang ; Qiao, Rong ; Zhang, Wei ; Qian, Ji ; Wang, Jiucun ; Chen, Hongyan ; Wei, Qingyi ; Han, Baohui ; Lu, Daru</creator><creatorcontrib>Wu, Wenting ; Li, Huan ; Wang, Huibo ; Zhao, Xueying ; Gao, Zhiqiang ; Qiao, Rong ; Zhang, Wei ; Qian, Ji ; Wang, Jiucun ; Chen, Hongyan ; Wei, Qingyi ; Han, Baohui ; Lu, Daru</creatorcontrib><description>Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that removes platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to individual differences in the outcome of patients after chemotherapy. This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment were enrolled in this study. Four potentially functional XPD polymorphisms (Arg(156)Arg, Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or PCR-based sequencing.
Variant genotypes of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln were significantly associated with poorer NSCLC survival (P = 0.006, 0.006, 0.014, respectively, by log-rank test). The most common haplotype GCA (in order of Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) also exhibited significant risk effect on NSCLC survival (log-rank P = 0.001). This effect was more predominant for patients with stage IIIB disease (P = 2.21×10(-4), log-rank test). Increased risks for variant haplotypes of XPD were also observed among patients with performance status of 0-1 and patients with adenocarcinoma. However, no significant associations were found between these polymorphisms, chemotherapy response and PFS.
Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0033200</identifier><identifier>PMID: 22479369</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adenocarcinoma ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Apoptosis ; Asian Continental Ancestry Group - genetics ; Biology ; Cancer ; Cancer therapies ; Carboplatin - administration & dosage ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - ethnology ; Carcinoma, Non-Small-Cell Lung - genetics ; Care and treatment ; Chemotherapy ; China ; Cisplatin - administration & dosage ; Clinical outcomes ; Deoxyribonucleic acid ; Disease ; Disease-Free Survival ; DNA ; DNA damage ; DNA helicase ; DNA repair ; Drug Administration Schedule ; Epidemiology ; Experimental design ; Female ; Gene Frequency ; Genetic aspects ; Genetic engineering ; Genetic polymorphisms ; Genetic testing ; Genotype ; Genotypes ; Glutamine ; Haplotypes ; Humans ; Influence ; Ionization ; Laboratories ; Life sciences ; Lung cancer ; Lung diseases ; Lung Neoplasms - drug therapy ; Lung Neoplasms - ethnology ; Lung Neoplasms - genetics ; Male ; Mass spectrometry ; Mass spectroscopy ; Medical prognosis ; Medical research ; Medicine ; Melanoma ; Middle Aged ; Multiple myeloma ; Multivariate Analysis ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Nucleotide excision repair ; Oncology ; Patient outcomes ; Patients ; Platinum ; Polymorphism, Single Nucleotide ; Prognosis ; Rankings ; Repair ; Respiratory diseases ; Skin cancer ; Small cell lung cancer ; Survival ; Treatment Outcome ; Xeroderma pigmentosum ; Xeroderma Pigmentosum Group D Protein - genetics ; XPD protein</subject><ispartof>PloS one, 2012-03, Vol.7 (3), p.e33200-e33200</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>2012 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Wu et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c691t-c51b357d0758db9a61ac98b8669a8cd5b92582a58e4698ee603397c4fe0f2bb43</citedby><cites>FETCH-LOGICAL-c691t-c51b357d0758db9a61ac98b8669a8cd5b92582a58e4698ee603397c4fe0f2bb43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315552/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3315552/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22479369$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Wenting</creatorcontrib><creatorcontrib>Li, Huan</creatorcontrib><creatorcontrib>Wang, Huibo</creatorcontrib><creatorcontrib>Zhao, Xueying</creatorcontrib><creatorcontrib>Gao, Zhiqiang</creatorcontrib><creatorcontrib>Qiao, Rong</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Qian, Ji</creatorcontrib><creatorcontrib>Wang, Jiucun</creatorcontrib><creatorcontrib>Chen, Hongyan</creatorcontrib><creatorcontrib>Wei, Qingyi</creatorcontrib><creatorcontrib>Han, Baohui</creatorcontrib><creatorcontrib>Lu, Daru</creatorcontrib><title>Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that removes platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to individual differences in the outcome of patients after chemotherapy. This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment were enrolled in this study. Four potentially functional XPD polymorphisms (Arg(156)Arg, Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or PCR-based sequencing.
Variant genotypes of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln were significantly associated with poorer NSCLC survival (P = 0.006, 0.006, 0.014, respectively, by log-rank test). The most common haplotype GCA (in order of Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) also exhibited significant risk effect on NSCLC survival (log-rank P = 0.001). This effect was more predominant for patients with stage IIIB disease (P = 2.21×10(-4), log-rank test). Increased risks for variant haplotypes of XPD were also observed among patients with performance status of 0-1 and patients with adenocarcinoma. However, no significant associations were found between these polymorphisms, chemotherapy response and PFS.
Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.</description><subject>Adenocarcinoma</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Apoptosis</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Biology</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carboplatin - administration & dosage</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - ethnology</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>China</subject><subject>Cisplatin - administration & dosage</subject><subject>Clinical outcomes</subject><subject>Deoxyribonucleic acid</subject><subject>Disease</subject><subject>Disease-Free Survival</subject><subject>DNA</subject><subject>DNA damage</subject><subject>DNA helicase</subject><subject>DNA repair</subject><subject>Drug Administration Schedule</subject><subject>Epidemiology</subject><subject>Experimental design</subject><subject>Female</subject><subject>Gene Frequency</subject><subject>Genetic aspects</subject><subject>Genetic engineering</subject><subject>Genetic polymorphisms</subject><subject>Genetic testing</subject><subject>Genotype</subject><subject>Genotypes</subject><subject>Glutamine</subject><subject>Haplotypes</subject><subject>Humans</subject><subject>Influence</subject><subject>Ionization</subject><subject>Laboratories</subject><subject>Life sciences</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - ethnology</subject><subject>Lung Neoplasms - genetics</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Melanoma</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multivariate Analysis</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Nucleotide excision repair</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Platinum</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Prognosis</subject><subject>Rankings</subject><subject>Repair</subject><subject>Respiratory diseases</subject><subject>Skin cancer</subject><subject>Small cell lung cancer</subject><subject>Survival</subject><subject>Treatment Outcome</subject><subject>Xeroderma pigmentosum</subject><subject>Xeroderma Pigmentosum Group D Protein - genetics</subject><subject>XPD protein</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk12L1DAUhoso7jr6D0QDguJFx3z0KzfCMq46sLDiF96FND2dZkmTmrTi3PrLzex0lxnZCym0IX3Oe855k5MkTwleElaSN1du8laa5eAsLDFmjGJ8LzklnNG0oJjdP1ifJI9CuMI4Z1VRPExOKM1Kzgp-mvw5b1tQI3ItGpzZ9s4PnQ59QNqiH5_eIWeRMtpqJQ1y06hcD-EaNnLUdurTWgZokOqgd2MHXg5b1DqPVp22EABZZ9PQS2OQgvgyk90gJa0Cj4aoAHYMj5MHrTQBnszfRfLt_fnX1cf04vLDenV2kaqCkzFVOalZXja4zKum5rIgUvGqjg1xWakmrznNKyrzCrKCVwBFtISXKmsBt7SuM7ZInu91B-OCmO0LgjCaMc4qTiOx3hONk1di8LqXfiuc1OJ6w_mNkH7UyoBocEPrgtG64lnGKa4xritZNi3hTd4QiFpv52xT3UOjYqdemiPR4z9Wd2LjfgnGSJ7nu2JezQLe_ZwgjKLXYWeitOCmIDinFS32Zb_4h7y7uZnayFi_tq2LadVOU5xlZYlxRqNli2R5BxWfBnqt4lVrddw_Cnh9FBCZEX6PGzmFINZfPv8_e_n9mH15wHYgzdgFZ6ZROxuOwWwPKu9C8NDeekyw2E3KjRtiNylinpQY9uzwfG6DbkaD_QVFFQ8b</recordid><startdate>20120329</startdate><enddate>20120329</enddate><creator>Wu, Wenting</creator><creator>Li, Huan</creator><creator>Wang, Huibo</creator><creator>Zhao, Xueying</creator><creator>Gao, Zhiqiang</creator><creator>Qiao, Rong</creator><creator>Zhang, Wei</creator><creator>Qian, Ji</creator><creator>Wang, Jiucun</creator><creator>Chen, Hongyan</creator><creator>Wei, Qingyi</creator><creator>Han, Baohui</creator><creator>Lu, Daru</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120329</creationdate><title>Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients</title><author>Wu, Wenting ; Li, Huan ; Wang, Huibo ; Zhao, Xueying ; Gao, Zhiqiang ; Qiao, Rong ; Zhang, Wei ; Qian, Ji ; Wang, Jiucun ; Chen, Hongyan ; Wei, Qingyi ; Han, Baohui ; Lu, Daru</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c691t-c51b357d0758db9a61ac98b8669a8cd5b92582a58e4698ee603397c4fe0f2bb43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adenocarcinoma</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Apoptosis</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Biology</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carboplatin - administration & dosage</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - ethnology</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>China</topic><topic>Cisplatin - administration & dosage</topic><topic>Clinical outcomes</topic><topic>Deoxyribonucleic acid</topic><topic>Disease</topic><topic>Disease-Free Survival</topic><topic>DNA</topic><topic>DNA damage</topic><topic>DNA helicase</topic><topic>DNA repair</topic><topic>Drug Administration Schedule</topic><topic>Epidemiology</topic><topic>Experimental design</topic><topic>Female</topic><topic>Gene Frequency</topic><topic>Genetic aspects</topic><topic>Genetic engineering</topic><topic>Genetic polymorphisms</topic><topic>Genetic testing</topic><topic>Genotype</topic><topic>Genotypes</topic><topic>Glutamine</topic><topic>Haplotypes</topic><topic>Humans</topic><topic>Influence</topic><topic>Ionization</topic><topic>Laboratories</topic><topic>Life sciences</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - ethnology</topic><topic>Lung Neoplasms - genetics</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Melanoma</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multivariate Analysis</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Nucleotide excision repair</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Platinum</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Prognosis</topic><topic>Rankings</topic><topic>Repair</topic><topic>Respiratory diseases</topic><topic>Skin cancer</topic><topic>Small cell lung cancer</topic><topic>Survival</topic><topic>Treatment Outcome</topic><topic>Xeroderma pigmentosum</topic><topic>Xeroderma Pigmentosum Group D Protein - genetics</topic><topic>XPD protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Wenting</creatorcontrib><creatorcontrib>Li, Huan</creatorcontrib><creatorcontrib>Wang, Huibo</creatorcontrib><creatorcontrib>Zhao, Xueying</creatorcontrib><creatorcontrib>Gao, Zhiqiang</creatorcontrib><creatorcontrib>Qiao, Rong</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Qian, Ji</creatorcontrib><creatorcontrib>Wang, Jiucun</creatorcontrib><creatorcontrib>Chen, Hongyan</creatorcontrib><creatorcontrib>Wei, Qingyi</creatorcontrib><creatorcontrib>Han, Baohui</creatorcontrib><creatorcontrib>Lu, Daru</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Wenting</au><au>Li, Huan</au><au>Wang, Huibo</au><au>Zhao, Xueying</au><au>Gao, Zhiqiang</au><au>Qiao, Rong</au><au>Zhang, Wei</au><au>Qian, Ji</au><au>Wang, Jiucun</au><au>Chen, Hongyan</au><au>Wei, Qingyi</au><au>Han, Baohui</au><au>Lu, Daru</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-03-29</date><risdate>2012</risdate><volume>7</volume><issue>3</issue><spage>e33200</spage><epage>e33200</epage><pages>e33200-e33200</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Xeroderma pigmentosum group D (XPD) codes for a DNA helicase involved in nucleotide excision repair that removes platinum-induced DNA damage. Genetic polymorphisms of XPD may affect DNA repair capacity and lead to individual differences in the outcome of patients after chemotherapy. This study aims to identify whether XPD polymorphisms affect clinical efficacy among advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
353 stage III-IV NSCLC patients receiving platinum-based chemotherapy as the first-line treatment were enrolled in this study. Four potentially functional XPD polymorphisms (Arg(156)Arg, Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry or PCR-based sequencing.
Variant genotypes of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln were significantly associated with poorer NSCLC survival (P = 0.006, 0.006, 0.014, respectively, by log-rank test). The most common haplotype GCA (in order of Asp(312)Asn, Asp(711)Asp and Lys(751)Gln) also exhibited significant risk effect on NSCLC survival (log-rank P = 0.001). This effect was more predominant for patients with stage IIIB disease (P = 2.21×10(-4), log-rank test). Increased risks for variant haplotypes of XPD were also observed among patients with performance status of 0-1 and patients with adenocarcinoma. However, no significant associations were found between these polymorphisms, chemotherapy response and PFS.
Our study provides evidence for the predictive role of XPD Asp(312)Asn, Asp(711)Asp and Lys(751)Gln polymorphisms/haplotype on NSCLC prognosis in inoperable advanced NSCLC patients treated with platinum-based chemotherapy.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>22479369</pmid><doi>10.1371/journal.pone.0033200</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2012-03, Vol.7 (3), p.e33200-e33200 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1324393892 |
| source | Public Library of Science (PLoS) Journals Open Access; MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adenocarcinoma Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Apoptosis Asian Continental Ancestry Group - genetics Biology Cancer Cancer therapies Carboplatin - administration & dosage Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - ethnology Carcinoma, Non-Small-Cell Lung - genetics Care and treatment Chemotherapy China Cisplatin - administration & dosage Clinical outcomes Deoxyribonucleic acid Disease Disease-Free Survival DNA DNA damage DNA helicase DNA repair Drug Administration Schedule Epidemiology Experimental design Female Gene Frequency Genetic aspects Genetic engineering Genetic polymorphisms Genetic testing Genotype Genotypes Glutamine Haplotypes Humans Influence Ionization Laboratories Life sciences Lung cancer Lung diseases Lung Neoplasms - drug therapy Lung Neoplasms - ethnology Lung Neoplasms - genetics Male Mass spectrometry Mass spectroscopy Medical prognosis Medical research Medicine Melanoma Middle Aged Multiple myeloma Multivariate Analysis Non-small cell lung cancer Non-small cell lung carcinoma Nucleotide excision repair Oncology Patient outcomes Patients Platinum Polymorphism, Single Nucleotide Prognosis Rankings Repair Respiratory diseases Skin cancer Small cell lung cancer Survival Treatment Outcome Xeroderma pigmentosum Xeroderma Pigmentosum Group D Protein - genetics XPD protein |
| title | Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20polymorphisms%20in%20XPD%20on%20clinical%20outcomes%20of%20platinum-based%20chemotherapy%20for%20Chinese%20non-small%20cell%20lung%20cancer%20patients&rft.jtitle=PloS%20one&rft.au=Wu,%20Wenting&rft.date=2012-03-29&rft.volume=7&rft.issue=3&rft.spage=e33200&rft.epage=e33200&rft.pages=e33200-e33200&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0033200&rft_dat=%3Cgale_plos_%3EA477004260%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1324393892&rft_id=info:pmid/22479369&rft_galeid=A477004260&rft_doaj_id=oai_doaj_org_article_d0d2b632b8944920b00b8a7df19d5d1e&rfr_iscdi=true |